GO
Loading...

Actavis Inc

More

  • Dec 18- Hedge fund Paulson& Co has taken a stake in specialty pharmaceuticals company Salix Pharmaceuticals Ltd as the company recovers from inventory issues and the departure of its chief financial officer, according to people familiar with the matter. The fund has recently taken a number of large positions in healthcare companies, including Shire PLC, where...

  • Dec 17- Tetraphase Pharmaceuticals Inc said its antibiotic to treat complicated intra-abdominal infections was as effective as Merck& co Inc's ertapenem in a late-stage study. Tetraphase is also testing the drug against Johnson& Johnson's levofloxacin to treat complicated urinary tract infections in another late-stage study, the results of which are...

  • Judge halts Alzheimer's drug swap until July Monday, 15 Dec 2014 | 5:27 PM ET

    District Judge Robert Sweet told Dublin- based Actavis PLC to continue making the drug Namenda available for 30 days after generic alternatives become available on July 11 "in order to allow for an orderly transition." His injunction orders the company to inform doctors and pharmacists of the decision and tells Actavis not to impose any hurdles for filling...

  • Schneiderman: Judge halts Alzheimer's drug swap Thursday, 11 Dec 2014 | 6:15 PM ET

    ALBANY, N.Y.— New York's attorney general says a federal judge has ordered a manufacturer to halt plans to immediately discontinue its widely used Alzheimer's drug, allegedly in an effort to drive patients to its newer patented drug. Attorney General Eric Schneiderman alleges anti-trust and state law violations by Dublin- based Actavis PLC and New York...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • BOSTON, Nov 26- Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.. One week after Allergan agreed to sell itself to rival Actavis Plc., Ackman wrote in his quarterly investment letter that his Pershing Square Capital Management, the Botox-maker's biggest...

  • *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures pointed to a higher open on Monday, indicating that major indexes would move further into record territory on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday,...

  • US STOCKS-Futures rise, boosted by merger activity Monday, 24 Nov 2014 | 8:14 AM ET

    *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures rose on Monday, indicating that major indexes would move further into record territory, on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday, with the Dow and S&P...

  • Goldman Sachs Group Inc retained its No. 1 position as M&A adviser with deals worth $877 billion, followed by JPMorgan Chase& Co with $651 billion and Citigroup Inc with $633 billion. The $66.4 billion bid for Allergan Inc by Actavis PLC this week more than doubled the total value of deals in the healthcare sector to $364 billion. Halliburton Co's plans to buy...

  • Valeant slashes stake in Allergan after losing bid Thursday, 20 Nov 2014 | 7:14 PM ET

    Nov 20- Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent from 9.7 percent, three days after Actavis Plc trumped its offer for the Botox maker. Pershing Square Capital Management informed Valeant that PS Fund 1 sold all of its 2.2 million shares in Allergan allocated to Valeant USA, Valeant said in a regulatory filing.

  • Nov 20- Canada's Valeant Pharmaceuticals International Inc said it may buy back up to $2 billion worth of securities, replacing a previous $1.5 billion program under which it bought back no securities. The announcement comes a few days after acquisition-hungry Valeant's $54 billion offer to buy Botox maker Allergan Inc was trumped by Actavis Plc's $66...

  • *Nikkei erases gains, Asia shares hit by weak commodity prices. TOKYO, Nov 19- Japanese shares gave up early gains on Wednesday as investors booked profits after Prime Minister Shinzo Abe delayed a tax hike and said he would call a snap election to seek a fresh mandate for his economic policies. Japan's Nikkei erased earlier gains to stand flat by midday, showing...

  • TOKYO, Nov 19- Japanese stocks rose on Wednesday as investors held out hope for more robust growth after Prime Minister Shinzo Abe delayed a tax hike and called an early election to seek a fresh mandate for his aggressive policies to shore up the economy. MSCI's broadest index of Asia-Pacific shares outside Japan was a touch lower while Japan's Nikkei rose 0.6...

  • Actavis Plc, Gilead Sciences and other biotechs were among the biggest drivers, a day after Allergan agreed to be bought by Actavis. Shares of Actavis were up 8.7 percent at $269.60, helped by bullish analyst notes, while Gilead's stock rose 3.3 percent to $103.71 percent. "A little bit of a risk trade is coming back on, and those are the areas for the M&A," said Uri...

  • Actavis Plc, Gilead Sciences, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.6 percent, while shares of Actavis were up 8.3 percent, Gilead's rose 3.3 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • US STOCKS-S&P 500 hits record, healthcare leads gains Tuesday, 18 Nov 2014 | 1:45 PM ET

    Actavis Plc, Gilead, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.4 percent, while shares of Actavis were up 7.7 percent, Gilead's rose 2.9 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • US STOCKS-S&P 500 hits record again; Actavis rallies Tuesday, 18 Nov 2014 | 11:01 AM ET

    NEW YORK, Nov 18- U.S. stocks rose on Tuesday, lifting the S&P 500 to a record high, boosted by healthcare after Actavis' acquisition of Allergan triggered bullish analyst notes. Allergan on Monday accepted a $66 billion takeover bid from Actavis Plc in cash and stock. At least two analysts raised Actavis' price target, one to as high as $300.

  • A day after shock data showing Japan slipping into recession had rattled financial markets, Japan's Nikkei rose 1.7 percent, erasing about a half of Monday's 3.0 percent fall. Prime Minister Shinzo Abe is expected to announce later in the day that he is calling a snap election, banking on the ruling Liberal Democrat Party trouncing a weak opposition to reaffirm...

  • *Baker Hughes rallies, Halliburton tumbles after deal. Shares of Baker Hughes, up 8.9 percent, and Allergan, up 5.3 percent, gave the S&P 500 its biggest boost after Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis. "It shows the strength of the overall market that you could have this recession news out of Japan, and yet have the...